Bio-Connect

PD-L1 antibody

GTX104763
GeneTex
ApplicationsFlow Cytometry, ImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetCD274
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    PD-L1 antibody
  • Delivery Days Customer
    9
  • Antibody Specificity
    This antibody is specific for human PDL1 protein, and it does not cross react with human PDL2 protein.
  • Application Supplier Note
    WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Flow Cytometry, ImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.97 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID29126
  • Target name
    CD274
  • Target description
    CD274 molecule
  • Target synonyms
    B7 homolog 1; B7-H; B7H1; CD274 antigen; hPD-L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL1; PD-L1; programmed cell death 1 ligand 1
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ9NZQ7
  • Protein Name
    Programmed cell death 1 ligand 1
  • Scientific Description
    Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.
  • Reactivity
    Human
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Inhibition of Na+/H+ exchanger (NHE) 7 by 5-(N-ethyl-N-isopropyl)-Amiloride displays anti-cancer activity in non-small cell lung cancer by disrupting cancer stem cell activity and downregulating PD-L1 expression.
    Read more
  • Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
    Read more
  • A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
    Read more
  • PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
    Read more
  • Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway.
    Read more
  • Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. Hung YH et al., 2022, Am J Cancer Res
    Read more
  • Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients. Omenai SA et al., 2022, PLoS One
    Read more
  • miR-4759 suppresses breast cancer through immune checkpoint blockade. Lin YZ et al., 2022, Comput Struct Biotechnol J
    Read more
  • Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Asrini R et al., 2022 Feb, Mol Clin Oncol
    Read more
  • Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer. Li L et al., 2021 May, Cancer Sci
    Read more